Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Liver Cirrhosis

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 21 articles: HTML format

Single Articles

September 2025
1. NOUREDDIN M, Shringarpure R, Yale K
   Efruxifermin in Compensated Liver Cirrhosis Caused by MASH. Reply.
   N Engl J Med. 2025;393:10.
   PubMed    
   
   
   
2. YU L
   Efruxifermin in Compensated Liver Cirrhosis Caused by MASH.
   N Engl J Med. 2025;393:10.
   PubMed    
   
   
   June 2025
3. GARCIA-TSAO G
   Redefining End Points in MASH Cirrhosis.
   N Engl J Med. 2025;392:2475-2477.
   PubMed    
   
   
   May 2025
4. NOUREDDIN M, Rinella ME, Chalasani NP, Neff GW, et al
   Efruxifermin in Compensated Liver Cirrhosis Caused by MASH.
   N Engl J Med. 2025 May 9. doi: 10.1056/NEJMoa2502242.
   PubMed     Abstract available
   
   
   April 2025
5. SANYAL AJ, Newsome PN, Kliers I, Ostergaard LH, et al
   Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.
   N Engl J Med. 2025 Apr 30. doi: 10.1056/NEJMoa2413258.
   PubMed     Abstract available
   
   
   October 2024
6. MEI Z, Pu J, Shao Z
   Two Trials of Therapeutics for MASH with Liver Fibrosis.
   N Engl J Med. 2024;391:1461-1462.
   PubMed    
   
   
   
7. POLYZOS SA
   Two Trials of Therapeutics for MASH with Liver Fibrosis.
   N Engl J Med. 2024;391:1461.
   PubMed    
   
   
   July 2024
8. SANYAL AJ, Bedossa P, Fraessdorf M, Neff GW, et al
   A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.
   N Engl J Med. 2024;391:311-319.
   PubMed     Abstract available
   
   
   June 2024
9. LOOMBA R, Hartman ML, Lawitz EJ, Vuppalanchi R, et al
   Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
   N Engl J Med. 2024 Jun 8. doi: 10.1056/NEJMoa2401943.
   PubMed     Abstract available
   
   
   May 2024
10. KOWDLEY KV, Levy C, Jones D
    Phase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis. Reply.
    N Engl J Med. 2024;390:1935-1936.
    PubMed    
    
    
    
11. HIRSCHFIELD GM, Kremer AE, Levy C
    Phase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis. Reply.
    N Engl J Med. 2024;390:1934-1935.
    PubMed    
    
    
    
12. IJICHI H
    Phase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis.
    N Engl J Med. 2024;390:1934.
    PubMed    
    
    
    
13. AREVALO-CANAS C, Arevalo-Serrano J
    Phase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis.
    N Engl J Med. 2024;390:1933-1934.
    PubMed    
    
    
    
14. HARRISON SA, Taub R
    A Phase 3 Trial of Resmetirom in NASH with Liver Fibrosis. Reply.
    N Engl J Med. 2024;390:1632-1633.
    PubMed    
    
    
    
15. SABET A
    A Phase 3 Trial of Resmetirom in NASH with Liver Fibrosis.
    N Engl J Med. 2024;390:1632.
    PubMed    
    
    
    February 2024
16. SCHNABL B
    PPAR Agonists in Primary Biliary Cholangitis.
    N Engl J Med. 2024;390:855-858.
    PubMed    
    
    
    
17. HIRSCHFIELD GM, Bowlus CL, Mayo MJ, Kremer AE, et al
    A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.
    N Engl J Med. 2024;390:783-794.
    PubMed     Abstract available
    
    
    
18. ASSIS DN
    Advancing Second-Line Treatment for Primary Biliary Cholangitis.
    N Engl J Med. 2024;390:853-854.
    PubMed    
    
    
    
19. HARRISON SA, Bedossa P, Guy CD, Schattenberg JM, et al
    A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
    N Engl J Med. 2024;390:497-509.
    PubMed     Abstract available
    
    
    November 2023
20. ROBBINS J, Halegoua-DeMarzio D, Basu Mallick A, Vijayvergia N, et al
    Liver Transplantation in a Woman with Mahvash Disease.
    N Engl J Med. 2023;389:1972-1978.
    PubMed     Abstract available
    
    
    
21. KOWDLEY KV, Bowlus CL, Levy C, Akarca US, et al
    Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
    N Engl J Med. 2023 Nov 13. doi: 10.1056/NEJMoa2306185.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Cirrhosis is free of charge.